Transitioning the chemical industry through biotechnologies

How is the growing synthetic biology sector evolving, why is it growing exponentially, and what are key players doing to stake their claim in an already crowded field that’s spurring an industry transition toward greater sustainability?

Join Hello Tomorrow and Solvay for a virtual panel discussion on February 14th at 4 pm CET to hear industry leaders share their experiences in biotech and their unique perspectives on start-up trends, how ideas can be transformed into high-value ventures, and some new venture capital funding opportunities for entrepreneurs.

We’ll hear from the early-stage startup DMC and the trials and triumphs they’ve faced in turning their idea into an innovation, developing new technology applications, building plants, and scaling up production capacities.

Learn how a mature start-up, Ginkgo, took an idea from the lab to the pilot plant to gain commercial traction and land its billion-dollar valuation. And why are more and more big corporations like Solvay collaborating with new entrepreneurs to help early-stage start-ups seed and grow, improve their technology, and develop the full-throated value proposition it takes to play successfully in this sector?

Register now for this free webinar and see where you fit in with the changing synthetic biology landscape.

Panelists:

Thomas Canova - Head of Solvay Circular Materials, Biotechnology and Solvay Ventures

Matt Lipscomb, PhD - CEO and Founder of DMC Biotechnologies

Po Bronson - General Partner at SOSV & Managing Director at IndieBio

Kevin Madden, VP Business Development, at Ginkgo Bioworks, Inc, a startup helping grow key ingredients for vaccines, crops that rely less on fossil fuel-based fertilizers, plant-based meat that tastes like the real thing, materials for the next generation of circular fashion, and so much more.

Moderated by Rainbow Lo, PhD, Chemistry & Materials Expert, Hello Tomorrow

Join us on February 14th at 4 pm CET!